ArticleOrphanet journal of rare diseases2025
Research hotspots and trends in malignant hyperthermia due to anesthesia from a global perspective: a bibliometric analysis from 1975 to 2024.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMalignant hyperthermia is a rare and highly lethal anesthesia emergency. We summarized the published articles on malignant hyperthermia to understand its development trends and provided meaningful recommendations for reducing the mortality rate.
methodsThe Web of Science core, PubMed Central and Scopus databases were searched from 1975 to 2024 to identify articles related to malignant hyperthermia. The retrieved documents were exported as full-text records via CiteSpace 6.4. R1 and R (BiblioShiny packages) were used to measure and visually analyze the number of articles, journals, keywords, and references.
resultsAccording to the bibliometric analysis, 1473 publications were published by research teams across 60 countries and regions. In 1473 publications, advanced economies accounted for 87.78% (n = 1303), while emerging and developing economies accounted for 12.22% (n = 170). In the past 40 years, advanced economies have dominated the field of MH research. The research on MH in emerging and developing economies have been rapidly increasing since 2010. Emerging and developing economies were paying more attention to MH diagnosis and the specific drug dantrolene. The most prolific country was the United States (n = 439, centrality = 0.55). The University of California System (n = 44, centrality = 0.04) had the highest number of articles. The journal ANESTHESIOLOGY was cocited 731 times and had the highest number of cocitations. From the timeline of keyword appearance, attention was devoted to dantrolene and succinylcholine in the 1980s. Since the 1990s, more research has focused on MH susceptibility and ryanodine receptors. Recently, amide anesthetics and spinal anesthesia-induced MH have received more attention.
conclusionsWe revealed the evolutionary path of MH research through bibliometric analysis. Owing to the lack of dantrolene and cooperation mechanisms in developing countries, the mortality rate caused by MH is still high. The government and pharmaceutical companies should collaborate to assist the availability and accessibility of dantrolene in developing countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.